Based on disclosed financials, 2024 revenue was KRW 19.39 million, the operating loss was KRW 1.92 billion and the net loss was KRW 1.44 billion. In 2025 revenue fell to KRW 102.18 million, down 47.31% year on year, while the operating loss widened to KRW 2.98 billion.
The net loss reached the KRW 2 billion range, and operating cash flow also recorded a deficit in the KRW 2 billion range. As of December 31, 2025, the equity ratio was 13.02% and the debt dependence ratio was 60.05%, both weaker than at end-2024.
Funding began with a convertible redeemable preferred share issuance disclosed on March 19, 2026, raising KRW 899.997 million at KRW 10,500 per share.
On November 6, 2026 the company decided on a third-party placement of 46,153 shares at KRW 13,000, raising KRW 599.989 million in operating funds with payment due November 16, 2026. Proceeds are earmarked for electroceutical R&D and operations, with planned uses of KRW 200 million in 2026 and KRW 200 million in 2027.
The 52-week high and low as of October 21, 2026 were KRW 7,930 and KRW 870, and TradingView data show a 52.10% decline over the past year. The stock closed at KRW 1,900 on November 6, down 5% from the prior session, and the current price at drafting is KRW 2,000. A shareholder report filed April 1, 2026 showed Capstone Partners holding 10.07%.